Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06522880 · ClinicalTrials.gov registry record
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
A clinical trial of Cytomegalovirus Infections, sponsored by University of Massachusetts, Worcester.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06522880: Recruiting study of Cytomegalovirus Infections, sponsored by University of Massachusetts, Worcester.
NCT06522880 is a study of Cytomegalovirus Infections that is actively recruiting participants, run by University of Massachusetts, Worcester. The registered enrollment target is 100 participants, below the 198-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06522880, a study of Cytomegalovirus Infections, is actively recruiting participants, sponsored by University of Massachusetts, Worcester.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of STAGE I of the CMV TransmIT Study is to determine the prevalence of CMV shedding in children up to and including 36 months of age in large group childcare centers and in staff who regularly work at the center. Participants will complete a health survey and provide one saliva sample for CMV PCR testing. In addition, infrastructure for the study will be developed (e.g. community engagement to build the network of centers, data pipelines, digital platform, sampling workflows) and participant sample collection at home will be piloted. These activities will inform the design of STAGE II.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST CMV PCR on saliva
Study Locations (1)
Massachusetts
- UMass Chan Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-08-10 |
| Est. Completion | 2027-12-31 |
What NCT06522880 shows while recruiting
NCT06522880 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which CMV PCR on saliva is the first listed.
NCT06522880 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06522880 about?
NCT06522880 is a clinical study titled "Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study". The goal of STAGE I of the CMV TransmIT Study is to determine the prevalence of CMV shedding in children up to and including 36 months of age in large group childcare centers and in staff who regularly work at the center. Participants will complete a health survey and provide one saliva sample for C...
What is the current status of trial NCT06522880?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-08-10. Estimated completion is 2027-12-31.
What conditions does trial NCT06522880 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections.
What interventions are being tested in trial NCT06522880?
The interventions under investigation include: CMV PCR on saliva (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06522880?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06522880 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06522880's enrollment target sits among peer trials
100 9th of 24 higher than 16 of 24 other Cytomegalovirus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytomegalovirus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
RECRUITING · Phase 2
-
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI